Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pilot Study of BCAA on Sleep

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03990909
Recruitment Status : Recruiting
First Posted : June 19, 2019
Last Update Posted : June 19, 2019
Sponsor:
Information provided by (Responsible Party):
Miranda M Lim, Portland VA Medical Center

Brief Summary:
Individuals will be recruited from the VA Portland Health Care System and the community affiliated with Oregon Health & Science University. Traumatic brain injury status will be assessed as a contributing factor. Subjects will be randomized to one of 3 groups (BCAA or one of 2 placebo conditions) and instructed to consume study product twice daily for 21 days. Self-report questionnaires, wrist actigraphy, pressure pain testing, and cognitive function will be assessed pre and post the experimental period.

Condition or disease Intervention/treatment Phase
Sleep Disorder Traumatic Brain Injury Dietary Supplement: Branched Chain Amino Acids Dietary Supplement: Rice Protein Dietary Supplement: Microcrystalline Cellulose Not Applicable

Detailed Description:

The goal of this proposal is to explore the feasibility of, and potential for, dietary supplementation with branched chain amino acids (BCAAs) to effect sleep quality and cognitive function in Veterans. The BCAAs (Leucine, Isoleucine, and Valine) cannot be synthesized endogenously (i.e., they must be obtained through the diet) and are the precursors to >50% of de novo glutamate and GABA synthesis in the brain, which are the primary excitatory and inhibitory neurotransmitters, respectively. Preclinical evidence strongly suggests that dietary BCAA supplementation restores normal sleep-wake patterns and cognitive function following TBI through a restoration in the global cortical excitation:inhibition ratio. BCAA supplementation has been studied extensively in healthy humans and in a variety of disease states, including following TBI, but not yet in Veterans in the chronic phase of recovery from TBI. BCAAs are a commercially available dietary supplement and very well tolerated with minimal side-effects.

Subjects will be randomized in a double-blind fashion through the VA Research Pharmacy to one of three groups: 1) BCAA; 60 g/day in two 30 g doses, 2) rice protein; 60 g/day in two 30 g doses, and 3) placebo; 60 g microcrystalline cellulose in two 30 g doses. BCAA and placebo will be prepared by the VA Research Pharmacy and dispensed in a blinded fashion to Veterans after demonstrating informed consent. Following a ~4-week period of baseline, Veterans will be instructed to consume study product after waking and ~6 hours later, on an empty stomach for a period of up to 21-days. Self-report questionnaires assessing sleep quality, cognitive function, trauma-related symptom severity, and other measures of mental and physical well-being will be administered before and after the experimental period. Wrist actigraphy will be continuously collected over the baseline and the experimental period. Cognitive function will be assessed before and after the experimental period using an established battery of neuropsychological tests (i.e., selected tests from WAIS, D-KEFS, HVLT, COWAT, among others. Pressure pain testing will be conducted before and after the experimental period.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Pilot Study of Dietary Supplementation With Branched Chain Amino Acids on Sleep
Actual Study Start Date : March 1, 2019
Estimated Primary Completion Date : August 1, 2024
Estimated Study Completion Date : August 1, 2025

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: BCAAs
60 grams of BCAA (2:1:1 ratio of Leucine:Isoleucine:Valine) consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21 days (42 total drinks).
Dietary Supplement: Branched Chain Amino Acids
60 grams of BCAA (2:1:1 ratio of Leucine:Isoleucine:Valine) consumed in two doses (30 grams each) mixed into 20 oz of water for up to21days (42 total drinks).
Other Name: BCAAs

Placebo Comparator: Rice Protein
Rice protein control group: 60 grams of rice protein consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21 days (42 total drinks).
Dietary Supplement: Rice Protein
60 grams of rice protein consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21days (42 total drinks).

Placebo Comparator: Microcrystalline Cellulose
Placebo control group: 60 grams of microcrystalline cellulose, consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21 days (42 total drinks).
Dietary Supplement: Microcrystalline Cellulose
60 grams of microcrystalline cellulose, consumed in two doses (30 grams each) mixed into 20 oz of water for up to 21days (42 total drinks).




Primary Outcome Measures :
  1. Recruitment and retention rates [ Time Frame: 5 weeks ]
    Number enrolled per month, proportion who complete the protocol

  2. Rates of adherence and treatment fidelity [ Time Frame: 5 weeks ]
    Proportion of subjects consuming full doses

  3. Assessment process and patient acceptability [ Time Frame: 5 weeks ]
    Proportion of questionnaires properly completed, actiwatches properly worn, and patient acceptance of protocol


Secondary Outcome Measures :
  1. Change in Insomnia Severity Index (ISI) [ Time Frame: Baseline; after 3 weeks of intervention ]
    Measures self-reported insomnia severity; total score range = 0-28 (higher total score = worse insomnia)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 89 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Veteran
  • English Speaking
  • Accessible via phone
  • Sleep problems

Exclusion Criteria:

  • Decisional impairment
  • Nickel allergy
  • Maple syrup urine disease or family history of disease
  • Allergy to sucralose
  • Currently taking BCAAs

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03990909


Contacts
Layout table for location contacts
Contact: Miranda M Lim, MD, PhD 503-220-8262 ext Ext. 57404 lmir@ohsu.edu

Locations
Layout table for location information
United States, Oregon
VA Portland Health Care System Recruiting
Portland, Oregon, United States, 97239
Contact: Miranda M Lim, MD, PhD    503-220-8262 ext 57404    lmir@ohsu.edu   
Sponsors and Collaborators
Portland VA Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Miranda M Lim, MD, PhD Portland VA Medical Center

Layout table for additonal information
Responsible Party: Miranda M Lim, Principal Investigator, Portland VA Medical Center
ClinicalTrials.gov Identifier: NCT03990909     History of Changes
Other Study ID Numbers: MIRB 4312
First Posted: June 19, 2019    Key Record Dates
Last Update Posted: June 19, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: All non-identifiable data will be made available to qualified researchers on request to the study PI.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Analytic Code
Time Frame: Information will be sent as soon as is practical and will be available as long as the PI is available.
Access Criteria: Legitimate research agenda, including but not limited to request to double-check presented or published results and novel analyses.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Brain Injuries
Brain Injuries, Traumatic
Sleep Wake Disorders
Parasomnias
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Craniocerebral Trauma
Trauma, Nervous System
Wounds and Injuries
Neurologic Manifestations
Signs and Symptoms
Mental Disorders